Sift Biosciences

4 known investors

Sift Biosciences develops T-cell immunotherapies for cancer and autoimmune diseases, using an AI-driven discovery platform combined with metagenomics and high-throughput cellular screening to identify microbially derived molecules that activate memory T cells. Its SIFT platform supports pipelines in oncology and autoimmunity, with the latter partnered with a large pharmaceutical company.